Roswell Park Cancer Institute
roswellpark.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
412
Active
84
Phase 3
6
Total enrollment
27,141
Pipeline matrix
Showing 40 of 83 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Therapeutic Testosterone | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 18 | ||
| Fluorouracil | — | — | — | 11 | |||
| Cyclophosphamide | — | — | 22 | ||||
| Oxaliplatin | — | — | — | 14 | |||
| Bevacizumab | — | — | — | 10 | |||
| Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine | — | — | — | — | 4 | ||
| Carfilzomib | — | — | — | — | 4 | ||
| SVN53-67/M57-KLH Peptide Vaccine | — | — | — | — | 4 | ||
| carboplatin | — | — | 11 | ||||
| sargramostim | — | — | — | 10 | |||
| Decitabine | — | — | — | — | 7 | ||
| leucovorin calcium | — | — | — | — | 7 | ||
| Leucovorin | — | — | — | — | 3 | ||
| Irinotecan | — | — | — | — | 3 | ||
| Pegcetacoplan | — | — | — | — | — | 2 | |
| Temozolomide | — | — | — | — | — | 2 | |
| dexamethasone | — | — | — | 13 | |||
| fludarabine phosphate | — | — | 11 | ||||
| etoposide | — | — | 8 | ||||
| lenalidomide | — | — | — | 5 | |||
| Propranolol | — | — | — | 3 | |||
| pegylated liposomal doxorubicin hydrochloride | — | — | — | 8 | |||
| Rintatolimod | — | — | — | 8 | |||
| Recombinant Interferon Alfa-2b | — | — | — | 6 | |||
| Sirolimus | — | — | — | — | 4 | ||
| Nivolumab | — | — | — | — | 4 | ||
| mycophenolate mofetil | — | — | — | — | — | 3 | |
| Propranolol Hydrochloride | — | — | — | — | — | 2 | |
| Melphalan Hydrochloride | — | — | — | — | — | 1 | |
| Verteporfin | — | — | — | — | — | 1 | |
| Olanzapine | — | — | — | — | — | 1 | |
| Pazopanib Hydrochloride | — | — | — | — | — | 1 | |
| Anti-HER2/HER3 Dendritic Cell Vaccine | — | — | — | — | — | 1 | |
| Nemtabrutinib | — | — | — | — | — | 1 | |
| Liposome-encapsulated Daunorubicin-Cytarabine | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| Cetuximab Sarotalocan Sodium | — | — | — | — | — | 1 | |
| TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes | — | — | — | — | — | 1 | |
| EC Aspirin | — | — | — | — | — | 1 |
43 more active programs hidden
Next readouts
- 2019-10-23
- 2020-03-23
- 2020-06-01
- 2021-03-04
- 2022-09-16
- 2023-08-21
- 2025-03-14
- 2025-04-10
- 2025-05-23
- 2026-02-05
Top conditions
- Leukemia22
- Unspecified Adult Solid Tumor, Protocol Specific22
- Lung Cancer20
- Lymphoma18
- Prostate Cancer17
- Colorectal Cancer14
- Malignant Solid Neoplasm11
- Recurrent Ovarian Carcinoma10
Frequently asked questions about Roswell Park Cancer Institute
- How many clinical trials does Roswell Park Cancer Institute have on ClinicalTrials.gov?
- Roswell Park Cancer Institute is listed as the lead sponsor on 412 clinical trials in ClinicalTrials.gov, 84 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Roswell Park Cancer Institute's trials are in Phase 3?
- 6 of Roswell Park Cancer Institute's trials are in Phase 3, spread across 83 active drug programs.
- What therapeutic areas does Roswell Park Cancer Institute focus on?
- Roswell Park Cancer Institute's most-studied conditions on ClinicalTrials.gov are Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Lung Cancer, Lymphoma, Prostate Cancer.
- When are Roswell Park Cancer Institute's next clinical trial readouts?
- Roswell Park Cancer Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma”, expected around 2019-10-23.